Merck KGaA announces first patient dosed in phase III study of oral cladribine in generalized myasthenia gravis
- Merck KGaA has dosed the first patient in the Phase III MyClad trial for oral cladribine in treating generalized myasthenia gravis (gMG).
- The MyClad trial is a global, randomized, double-blind, placebo-controlled study involving 240 patients.
- Cladribine capsules aim to selectively target B and T lymphocytes, potentially slowing disease progression and reducing treatment burden.
- gMG is a rare neuromuscular disorder causing muscle weakness, affecting approximately 700,000 people worldwide.
Read more
Kiyatec announces publication of groundbreaking study on 3D Predict Glioma in high-grade glioma patients
- Kiyatec's study on the 3D Predict Glioma test was published in Scientific Reports.
- The test significantly improves progression-free and overall survival in high-grade glioma (HGG) patients.
- The study enrolled 102 newly diagnosed HGG patients from multiple centers in the U.S.
- Patients identified as responders had a median progression-free survival increase of 5.8 months and overall survival increase of 7.6 months.
Read more
